Multivariate analyses in the validation cohort
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| FFS | |||
| Lymphocyte count (< 600/mm3 or < 8%) | 2.1 | 0.8-5.8 | .14 |
| Stage 4 disease | 2.2 | 1.0-4.7 | .04 |
| CD68high | 2.1 | 1.1-4.2 | .04 |
| Lymphocyte count (< 600/mm3 or < 8%) | 2.1 | 0.8-5.9 | .14 |
| Stage 4 disease | 1.8 | 0.8-3.9 | .13 |
| CD163high | 2.5 | 1.2-5.3 | .02 |
| OS | |||
| Age (≥ 45 y) | 2.5 | 0.9-7.1 | .08 |
| CD68high | 3.5 | 1.2-10.2 | .02 |
| Age (≥ 45 y) | 3.4 | 1.3-9.2 | .02 |
| CD163high | 3.9 | 1.3-11.9 | .02 |
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| FFS | |||
| Lymphocyte count (< 600/mm3 or < 8%) | 2.1 | 0.8-5.8 | .14 |
| Stage 4 disease | 2.2 | 1.0-4.7 | .04 |
| CD68high | 2.1 | 1.1-4.2 | .04 |
| Lymphocyte count (< 600/mm3 or < 8%) | 2.1 | 0.8-5.9 | .14 |
| Stage 4 disease | 1.8 | 0.8-3.9 | .13 |
| CD163high | 2.5 | 1.2-5.3 | .02 |
| OS | |||
| Age (≥ 45 y) | 2.5 | 0.9-7.1 | .08 |
| CD68high | 3.5 | 1.2-10.2 | .02 |
| Age (≥ 45 y) | 3.4 | 1.3-9.2 | .02 |
| CD163high | 3.9 | 1.3-11.9 | .02 |
HR indicates hazard ratio; and CI, confidence interval.